Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Rituximab in DLBCL or Follicular Lymphoma
NCT01889069Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2013
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Roche. Primary endpoint: Percentage of Participants With Administration-Associated Reactions at 54 months. Started Jul 2013; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01889069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889069.